文献速递肝病消化道肿瘤与早癌

微小RNA-7/生长停滞特异性蛋白6/TYRO3轴调控人肝细胞癌索拉非尼耐药细胞的生长与侵袭

A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2017-11-29

研究在体外和体内临床前模型中建立两种功能不同的索拉非尼耐药人Huh-7肝细胞癌细胞系,发现miR-7-5p(miR-7)是肝细胞癌的强效抑癌因子,TYRO3为其新功能靶点。TYRO3经磷脂酰肌醇3-激酶/蛋白激酶B通路调控Huh-7细胞增殖、迁移和侵袭,并随索拉非尼耐药获得而显著升高;miR-7过表达可沉默TYRO3并抑制生长停滞特异性蛋白6介导的迁移和侵袭。

要点

  • miR-7-5p(miR-7)在体外和体内临床前模型中是肝细胞癌的强效抑癌因子。
  • TYRO3是miR-7的新功能靶点,经磷脂酰肌醇3-激酶/蛋白激酶B通路调控Huh-7细胞增殖、迁移和侵袭。
  • miR-7过表达可沉默TYRO3,抑制生长停滞特异性蛋白6介导的Huh-7细胞迁移和侵袭。

核心结论

  • 研究识别出肝细胞癌获得索拉非尼耐药的机制,即通过TYRO3/磷脂酰肌醇3-激酶/蛋白激酶B信号转导通路的异常表达,且该机制可被miR-7过表达所克服。
  • 这些数据提示miR-7作为基于RNA的治疗手段用于治疗难治性和耐药性肝细胞癌的潜在作用。

研究设计与样本

  • 研究建立两种功能不同的索拉非尼耐药人Huh-7肝细胞癌细胞系,并在体外和体内临床前模型中研究miR-7-5p(miR-7)的作用。
  • 研究发表于Hepatology 2018;67:216-231。

主要发现

  • miR-7在体外和体内临床前模型中被鉴定为人肝细胞癌的强效抑癌因子。
  • TYRO3被鉴定为miR-7的新功能靶点,经磷脂酰肌醇3-激酶/蛋白激酶B通路调控Huh-7细胞增殖、迁移和侵袭,并随索拉非尼耐药获得而显著升高。
  • miR-7在索拉非尼敏感和索拉非尼耐药的Huh-7细胞中均有效沉默TYRO3表达,抑制TYRO3/生长停滞特异性蛋白6介导的癌细胞迁移和侵袭。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carcinoma (HCC). However, the therapeutic effect of sorafenib is transient, and patients invariably develop sorafenib resistance (SR). Recently, TYRO3, a member of the TYRO3-AXL-MER family of receptor tyrosine kinases, was identified as being aberrantly expressed in a significant proportion of HCC; however, its role in SR is unknown. In this study, we generated two functionally distinct sorafenib-resistant human Huh-7 HCC cell lines in order to identify new mechanisms to abrogate acquired SR as well as new potential therapeutic targets in HCC. Initially, we investigated the effects of a microRNA (miR), miR-7-5p (miR-7), in both in vitro and in vivo preclinical models of human HCC and identified miR-7 as a potent tumor suppressor of human HCC. We identified TYRO3 as a new functional target of miR-7, which regulates proliferation, migration, and invasion of Huh-7 cells through the phosphoinositide 3-kinase/protein kinase B pathway and is markedly elevated with acquisition of SR. Furthermore, miR-7 effectively silenced TYRO3 expression in both sorafenib-sensitive and sorafenib-resistant Huh-7 cells, inhibiting TYRO3/growth arrest specific 6-mediated cancer cell migration and invasion. CONCLUSION: We identified a mechanism for acquiring SR in HCC that is through the aberrant expression of the TYRO3/phosphoinositide 3-kinase/protein kinase B signal transduction pathway, and that can be overcome by miR-7 overexpression. Taken together, these data suggest a potential role for miR-7 as an RNA-based therapeutic to treat refractory and drug-resistant HCC. (Hepatology 2018;67:216-231).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kabir TD, Ganda C, Brown RM, et al. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology. 2017. PMID: 28833396. doi:10.1002/hep.29478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。